EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of two gradient diffusion tests to determine susceptibility to aztreonam and ceftazidime–avibactam in combination

Ayesha Khan iD, Carmila Manuel, Richard Maynard, Romney M Humphries iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01736-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Ayesha Khan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Ceftazidime, Aztreonam, Azabicyclo Compounds, Anti-Bacterial Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The combination of aztreonam and ceftazidime–avibactam (ATM–CZA) is a last resort regimen against recalcitrant infections caused by metallo-β-lactamase (MBL)-producing organisms. Susceptibility testing is warranted due to emerging resistance to the combination, but there are no widely implemented methods for use in clinical laboratories. Here, we used a cohort of 100 Enterobacterales , Pseudomonas aeruginosa , and Stenotrophomonas maltophilia strains, including 68 MBL producers, to evaluate the performance of two ETEST strip-based synergy testing methods: the side-by-side (SS) method with an ATM ETEST placed next to a CZA ETEST (10 mm apart) and the strip cross (SX) method with a CZA ETEST placed perpendicularly on top of the ATM ETEST (at the 8 µg/mL mark). By reference broth microdilution (BMD), 89.1% (41/46) of the Enterobacterales, 15% (3/20) of the P. aeruginosa , and 97.1% (33/34) of the S. maltophilia isolates tested susceptible to the ATM–CZA combination. The SS method yielded 72% categorical agreement with BMD and 28 major errors (ME, 36.4%). Initial testing with the SX method yielded three ME , of which one was resolved upon repeat testing, yielding a final categorical agreement of 98% with BMD with two ME (2.6%). The SX method also yielded 100% reproducibility across three brands of Mueller Hinton agar (BD, Hardy, Remel). Our study demonstrates that the SX method is accurate, precise, and feasible for clinical laboratories to perform ATM–CZA susceptibility testing to guide use of the combination for treatment of multidrug-resistant gram-negative pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeAztreonamAzabicyclo CompoundsAnti-Bacterial AgentsPseudomonas aeruginosaDrug CombinationsStenotrophomonas maltophiliaMicrobial Sensitivity TestsEnterobacteriaceaeHumansbeta-LactamasesDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

EnterobacteriaceaePseudomonas aeruginosaStenotrophomonasantibiotic resistanceantimicrobial agentsantimicrobial combinationsdiagnosticsmetalloenzymesmultidrug resistancesusceptibility testing

Substanzen

CeftazidimeAztreonamAzabicyclo Compoundsavibactam, ceftazidime drug combinationDrug CombinationsAnti-Bacterial Agentsbeta-Lactamases

Autor:innen und Institutionen

  • Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

ORCID-Profile: Ayesha Khan, Romney M Humphries

Zitieren

APA

Khan, A., Manuel, C., Maynard, R., & Humphries, R. M. (2025). Evaluation of two gradient diffusion tests to determine susceptibility to aztreonam and ceftazidime–avibactam in combination. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01736-24

Vancouver

Khan A, Manuel C, Maynard R, Humphries RM. Evaluation of two gradient diffusion tests to determine susceptibility to aztreonam and ceftazidime–avibactam in combination. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01736-24

BibTeX
@article{Khan2025,
  author = {Khan, Ayesha and Manuel, Carmila and Maynard, Richard and Humphries, Romney M},
  title = {Evaluation of two gradient diffusion tests to determine susceptibility to aztreonam and ceftazidime–avibactam in combination},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01736-24}
}
Kostenlos starten →